CL2014003028A1 - Formulacion parenteral de clorhidrato de esmolol; metodo de produccion; kit farmaceutico; uso para tratar descompensacion cardiaca y/o renal y/o hipernatremia y/o acidosis hipercloramica. - Google Patents

Formulacion parenteral de clorhidrato de esmolol; metodo de produccion; kit farmaceutico; uso para tratar descompensacion cardiaca y/o renal y/o hipernatremia y/o acidosis hipercloramica.

Info

Publication number
CL2014003028A1
CL2014003028A1 CL2014003028A CL2014003028A CL2014003028A1 CL 2014003028 A1 CL2014003028 A1 CL 2014003028A1 CL 2014003028 A CL2014003028 A CL 2014003028A CL 2014003028 A CL2014003028 A CL 2014003028A CL 2014003028 A1 CL2014003028 A1 CL 2014003028A1
Authority
CL
Chile
Prior art keywords
hypernatremia
production
pharmaceutical kit
parenteral formulation
treat cardiac
Prior art date
Application number
CL2014003028A
Other languages
English (en)
Inventor
Rudolf Widmann
Original Assignee
Aop Orphan Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48407551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014003028(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aop Orphan Pharmaceuticals Ag filed Critical Aop Orphan Pharmaceuticals Ag
Publication of CL2014003028A1 publication Critical patent/CL2014003028A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2014003028A 2012-05-10 2014-11-07 Formulacion parenteral de clorhidrato de esmolol; metodo de produccion; kit farmaceutico; uso para tratar descompensacion cardiaca y/o renal y/o hipernatremia y/o acidosis hipercloramica. CL2014003028A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12167443 2012-05-10

Publications (1)

Publication Number Publication Date
CL2014003028A1 true CL2014003028A1 (es) 2015-06-19

Family

ID=48407551

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014003028A CL2014003028A1 (es) 2012-05-10 2014-11-07 Formulacion parenteral de clorhidrato de esmolol; metodo de produccion; kit farmaceutico; uso para tratar descompensacion cardiaca y/o renal y/o hipernatremia y/o acidosis hipercloramica.

Country Status (28)

Country Link
US (3) US20150087704A1 (es)
EP (1) EP2846776B1 (es)
JP (1) JP6220383B2 (es)
CN (1) CN104379134A (es)
AU (1) AU2013258031B2 (es)
BR (1) BR112014027870B1 (es)
CA (1) CA2872953C (es)
CL (1) CL2014003028A1 (es)
DK (1) DK2846776T3 (es)
EA (1) EA032344B1 (es)
ES (1) ES2794093T3 (es)
HK (1) HK1204265A1 (es)
HR (1) HRP20200897T1 (es)
HU (1) HUE049314T2 (es)
IL (1) IL235497A0 (es)
LT (1) LT2846776T (es)
MA (1) MA37500B1 (es)
MX (1) MX2014013556A (es)
MY (1) MY173900A (es)
NZ (1) NZ701429A (es)
PH (1) PH12014502494B1 (es)
PL (1) PL2846776T3 (es)
PT (1) PT2846776T (es)
SI (1) SI2846776T1 (es)
TN (1) TN2014000464A1 (es)
UA (1) UA115333C2 (es)
WO (1) WO2013167657A1 (es)
ZA (1) ZA201408149B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019122157A1 (en) * 2017-12-21 2019-06-27 Ipsol Ag A lyophilisate comprising esmolol and adenosine for use in cardioplegia
CN111848420A (zh) * 2020-07-22 2020-10-30 杭州煌森生物科技有限公司 一种盐酸艾司洛尔的新晶型及制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI277414B (en) 2001-01-12 2007-04-01 Baxter Int Esmolol formulation
US6310094B1 (en) * 2001-01-12 2001-10-30 Baxter International Inc. Ready-to-use esmolol solution
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
KR20080039954A (ko) * 2005-08-31 2008-05-07 오노 야꾸힝 고교 가부시키가이샤 점적용 주사제
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
CN101903024A (zh) 2007-12-21 2010-12-01 Aop孤儿药品股份公司 用于肠胃外给药超短效β-肾上腺素受体拮抗剂的药物组合物
CN102106846A (zh) * 2009-12-23 2011-06-29 南京海辰药业有限公司 左旋盐酸艾司洛尔药物组合物及其制备方法

Also Published As

Publication number Publication date
PL2846776T3 (pl) 2020-09-21
CA2872953C (en) 2020-04-07
EP2846776B1 (en) 2020-04-15
US11963940B2 (en) 2024-04-23
PT2846776T (pt) 2020-05-28
EA201491841A1 (ru) 2015-02-27
LT2846776T (lt) 2020-06-25
PH12014502494A1 (en) 2015-01-12
HRP20200897T1 (hr) 2020-11-27
US20150087704A1 (en) 2015-03-26
EP2846776A1 (en) 2015-03-18
JP6220383B2 (ja) 2017-10-25
DK2846776T3 (da) 2020-06-15
UA115333C2 (uk) 2017-10-25
WO2013167657A1 (en) 2013-11-14
CA2872953A1 (en) 2013-11-14
AU2013258031B2 (en) 2017-08-03
BR112014027870A8 (pt) 2023-01-17
MY173900A (en) 2020-02-26
ES2794093T3 (es) 2020-11-17
US20170326095A1 (en) 2017-11-16
TN2014000464A1 (en) 2016-03-30
AU2013258031A1 (en) 2014-11-20
MA37500B1 (fr) 2016-12-30
US20220249424A1 (en) 2022-08-11
JP2015520142A (ja) 2015-07-16
IL235497A0 (en) 2014-12-31
MX2014013556A (es) 2015-01-16
PH12014502494B1 (en) 2015-01-12
BR112014027870A2 (pt) 2017-06-27
SI2846776T1 (sl) 2020-08-31
MA37500A1 (fr) 2016-03-31
NZ701429A (en) 2016-04-29
HUE049314T2 (hu) 2020-09-28
BR112014027870B1 (pt) 2023-04-25
HK1204265A1 (en) 2015-11-13
ZA201408149B (en) 2016-08-31
EA032344B1 (ru) 2019-05-31
CN104379134A (zh) 2015-02-25

Similar Documents

Publication Publication Date Title
SMT201600157B (it) Composti di carbammoilpiridone policiclici e loro uso farmaceutico
PE20150883A1 (es) Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso
CO6930363A2 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
GT201500053A (es) Composicion farmaceutica recubierta que contiene regorafenib
CL2014001729A1 (es) Compuestos derivados de tieno (3,2-d) pirimidina, inhibidores de quinasas; composicion farmaceutica; y su uso en la prevencion o tratamiento de una enfermedad relacionada con quinasas como cancer.
CO6900118A2 (es) Métodos para tratar el cancer por el uso de antagonistas de unión al eje pd-1e inhibidores de mek
CO6801774A2 (es) Compuestos de benzotiazol y su uso farmacéutico
CL2013001891A1 (es) Compuestos heterociclicos fusionados; composicion farmaceutica y uso en el tratamiento de la degeneracion macular asociada con la edad.
CO7020907A2 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmacéuticas y métodos de uso de los mismos
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
CO6950473A2 (es) Novedosos derivados de purina y su uso en el tratamiento de enfermedades
EA201391285A1 (ru) Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена
CO7000778A2 (es) Derivados de pirazolopiridina, su procedimiento de preparación y su uso terapéutico
EA201270722A1 (ru) Формы рифаксимина и их применение
BR112015002755A2 (pt) derivado de ácido hialurônico, método de preparação de derivado de ácido hialurônico, método de modificação de derivado de ácido hialurônico e uso de derivados
PT3004108T (pt) Derivados de pirazolo-pirrolidin-4-ona como inibidores de bet e a sua utilização no tratamento de doenças
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
CL2014000849A1 (es) Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
BR112015002706A2 (pt) niclosamida e seus derivados para uso no tratamento de tumores sólidos
CO6970609A2 (es) Composición farmacéutica y métodos de uso de derivados de 4-pregenen-11ß-17-21-triol-3,20-diona
CL2014001861A1 (es) Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia.
HK1218709A1 (zh) 新水楊酸衍生物、其藥學上可接受的鹽、其組合物以及其使用方法
CL2014000267A1 (es) Formulacion farmaceutica liquida que comprende ketoprofeno, amitriptilina y oximetazolina; kit farmaceutico; metodo para prevenir o tratar la inflamacion.
CL2014001959A1 (es) Compuestos derivados de fenil-1h-imidazo[1,2-b]pirazol sustituidos; procedimiento de preparacion; composicion farmaceutica; y el uso en el tratamiento del cancer.
HK1212255A1 (en) Artemisinin and its derivatives for use in the treatment of kidney disease